Monoclonal Antibody (mAb) Licensing Deal Benchmarks
Market Analysis
Monoclonal antibodies remain the backbone of biologic drug development, representing the largest share of biopharma licensing activity by deal count. Phase 2 mAb deals in immunology achieve a median total deal value of $2.5B, with upfront payments from $251M to $760M. The well-characterized development pathway and commercial predictability of mAbs provide deal certainty that newer modalities cannot yet match.
Milestone structures for mAb deals allocate $406M to development, $710M to regulatory, and $913M to commercial milestones. The overall 19/81 upfront/milestone split reflects the de-risked clinical pathway at Phase 2.
Royalty rates for mAb licensing range from 13.2% to 22.1% at the base tier, escalating to 26.1% on peak sales. Differentiated targets, best-in-class efficacy profiles, and subcutaneous formulations command premium royalty rates. Biosimilar exposure risk increasingly influences royalty term negotiations.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average total deal value for a monoclonal antibody licensing deal?
How do mAb deal terms differ by therapeutic area?
What royalty rates are standard for mAb licensing deals?
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating